6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $77M | -$8M | 74.7% | -10.2% | -$5M | — | $68M |
| 2024 | $71M | -$47M | 70.3% | -69.3% | -$13M | — | $71M |
| 2023 | $76M | -$92M | 67.6% | -124.5% | -$37M | — | $87M |
| 2022 | $82M | -$141M | 67.5% | -174.1% | -$75M | — | $131M |
| 2021 | $80M | -$125M | 71.7% | -156.9% | -$107M | — | $225M |
| 2020 | $66M | -$62M | 73.0% | -95.9% | -$21M | — | $290M |
Over the past 5 years, Burning Rock Biotech Ltd's revenue has grown 3.2% per year. These are computed facts, not advice.
As of FY2025, Burning Rock Biotech Ltd reported — of total debt against $68M of cash.
In FY2025, gross margin was 74.7%, operating margin -10.2%, and net margin -10.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.